GENFIT S.A. - American Depositary Shares (GNFT)

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.

Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion.

The company is working on the first treatment that could make a difference in the itching associated with a liver disease.

The company is working on a treatment for a liver disease that can cause severe itching.

HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of 

Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC: 

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) 

Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.

It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today!

Following the FDA rejection, Intercept will restructure to focus on rare liver diseases.